Altimmune (ALT) Non Operating Income (2010 - 2026)

Altimmune (ALT) has 17 years of Non Operating Income data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 7.83% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $5.8 million, a 19.73% decrease from a year earlier, with the FY2025 full-year figure at $5.7 million, down 29.56% from the prior year.
• Non Operating Income for Q1 2026 stood at $1.7 million, up from $1.5 million in the prior quarter.
• Over the last five years, Non Operating Income for ALT reached as high as $2.4 million in Q1 2024 and fell as low as $69000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $1.5 million across 5 years, with a median of $1.7 million in 2023.
• Across the five-year window, Non Operating Income jumped 2400.0% in 2022 and tumbled 63.14% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $1.4 million in 2022, then soared by 38.21% to $2.0 million in 2023, then declined by 14.93% to $1.7 million in 2024, then slipped by 8.96% to $1.5 million in 2025, then advanced by 9.51% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $1.7 million in Q1 2026, $1.5 million in Q4 2025, and $1.8 million in Q3 2025.